| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Department of Internal Medicine III, University of Leipzig, D-04103 Leipzig, Germany
Address all correspondence and requests for reprints to: R. Paschke, M.D., Departmentof Internal Medicine III, University of Leipzig, Ph. Rosenthal Strasse 27, D-04103 Leipzig, Germany.
Constitutively activating TSH receptor mutations have recently been
detected in toxic nodules. In vitro studies suggest that
mutated receptor signaling constitutively elevates cAMP, which causes
hyperfunction and proliferation of thyrocytes. Therefore, toxic nodules
with constitutively activating somatic TSH receptor mutations should
result from clonal expansion of a single mutated cell. To test this
hypothesis, we studied the clonal origin of 27 toxic nodules. In 13 of
27 nodules, a somatic mutation in the TSH receptor was identified. A
PCR-based clonality assay that analyzes X-chromosome inactivation was
used. The assay amplifies a polymorphism located in the androgen
receptor gene. Of 27 toxic nodules studied, 23 (85%) were informative
for the polymorphism. In the group that contains a somatic mutation in
the TSH receptor, 10 of 11 cases showed nonrandom X inactivation,
indicating clonal expansion. In only one toxic nodule with a TSH
receptor mutation was random X inactivation detected. In the group
without detectable mutations in exons 9 and 10 of the TSH receptor and
exons 710 of the Gs
protein, only 6 of 12 toxic
nodules show nonrandom X-chromosome inactivation. Therefore, the
majority of toxic nodules with constitutively activating TSH receptor
mutations are of clonal origin. This finding supports the hypothesis
that toxic nodules arise from aberrant growth of a single cell. It is
widely accepted that somatic mutations might initiate monoclonal
growth. The TSH receptor mutations in these toxic nodules together with
Gs
mutations in others are the most likely candidates
for the initiation of this thyroid tumor. The clonal origin of toxic
nodules in the group without detected mutations in the TSH receptor or
the Gs
protein suggests somatic mutations in genes that
are unknown to date.
This article has been cited by other articles:
![]() |
H. I. Gozu, R. Bircan, K. Krohn, S. Muller, S. Vural, C. Gezen, H. Sargin, D. Yavuzer, M. Sargin, B. Cirakoglu, et al. Similar prevalence of somatic TSH receptor and Gs{alpha} mutations in toxic thyroid nodules in geographical regions with different iodine supply in Turkey. Eur. J. Endocrinol., October 1, 2006; 155(4): 535 - 545. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Krohn, D. Fuhrer, Y. Bayer, M. Eszlinger, V. Brauer, S. Neumann, and R. Paschke Molecular Pathogenesis of Euthyroid and Toxic Multinodular Goiter Endocr. Rev., June 1, 2005; 26(4): 504 - 524. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Jovanovic, B. Delahunt, B. McIver, N. L. Eberhardt, and S. K. G. Grebe Thyroid Gland Clonality Revisited: The Embryonal Patch Size of the Normal Human Thyroid Gland Is Very Large, Suggesting X-Chromosome Inactivation Tumor Clonality Studies of Thyroid Tumors Have to Be Interpreted with Caution J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3284 - 3291. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Eszlinger, K. Krohn, and R. Paschke Complementary DNA Expression Array Analysis Suggests a Lower Expression of Signal Transduction Proteins and Receptors in Cold and Hot Thyroid Nodules J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4834 - 4842. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Krohn and R. Paschke Progress in Understanding the Etiology of Thyroid Autonomy J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3336 - 3345. [Full Text] [PDF] |
||||
![]() |
E. M. Gabriel, E. R. Bergert, C. S. Grant, J. A. van Heerden, G. B. Thompson, and J. C. Morris Germline Polymorphism of Codon 727 of Human Thyroid-Stimulating Hormone Receptor Is Associated with Toxic Multinodular Goiter J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3328 - 3335. [Abstract] [Full Text] |
||||
![]() |
X. De Deken, C. Vilain, J. Van Sande, J. E. Dumont, and F. Miot Decrease of Telomere Length in Thyroid Adenomas without Telomerase Activity J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4368 - 4372. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |